For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …

Eradicating tumor dormancy that develops following epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-
mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known …

The'hallmarks of cancer'are generally accepted as a set of genetic and epigenetic
alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows …

EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer
(NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ …

The BCL-2 protein family determines the commitment of cells to apoptosis, an ancient cell
suicide programme that is essential for development, tissue homeostasis and immunity. Too …

Resistance to chemotherapy and molecularly targeted therapies is a major problem facing
current cancer research. The mechanisms of resistance to'classical'cytotoxic …

Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified …